Palvella Therapeutics (PVLA) Amortization of Deferred Charges (2014 - 2020)
Palvella Therapeutics (PVLA) reported Amortization of Deferred Charges of $199000.0 for Q1 2020, down 45.52% quarter-over-quarter from $365251.0 in Q3 2014.
Palvella Therapeutics (PVLA) Amortization of Deferred Charges (2014 - 2020) Analysis & Trends
Palvella Therapeutics (PVLA) has 2 years of Amortization of Deferred Charges data on file, last reported at $199000.0 in Q1 2020.
- Amortization of Deferred Charges for Q1 2020 came in at $199000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2020 was $746202.0 (up 18.55% YoY), and the FY2019 annual result was $408000.0, changed N/A from the prior year.
- Amortization of Deferred Charges retreated to $199000.0 in Q1 2020 per PVLA's latest filing, from $365251.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $199000.0 in Q1 2020 and troughed at $199000.0 in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Palvella Therapeutics | 1.42 Bn | 1.16 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 199,000.00 |
| Mar 31, 2020 | 199,000.00 |
| Sep 30, 2014 | 365,251.00 |
| Sep 30, 2014 | 365,251.00 |
| Jun 30, 2014 | 181,951.00 |
| Jun 30, 2014 | 181,951.00 |
| Mar 31, 2014 | 82,230.00 |
| Mar 31, 2014 | 82,230.00 |